Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Mechanisms in fluid retention - Towards a mutual concept

    Research output: Contribution to journalReviewResearchpeer-review

  2. The age-related reduction in cerebral blood flow affects vertebral artery more than internal carotid artery blood flow

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Myocardial perfusion assessed with cardiac computed tomography in women without coronary heart disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Validation of non-invasive haemodynamic methods in patients with liver disease: the Finometer and the Task Force Monitor

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cholesteryl ester storage disease of clinical and genetic characterisation: A case report and review of literature

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Energy expenditure and loss of muscle and fat mass in patients with walled-off pancreatic necrosis: A prospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Acetaminophen toxicity induces mitochondrial complex I inhibition in human liver tissue

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Non-alcoholic fatty liver disease (NAFLD) affects about 25% of the population worldwide. NAFLD may be viewed as the hepatological manifestation of metabolic syndrome. Patients with metabolic syndrome due to diabetes or obesity have an increased risk of cardiovascular disease. This narrative review describes cardiometabolic effects of antidiabetic drugs in NAFLD.

METHODS: We conducted a systematic search in PubMed and manually scanned bibliographies in trial databases and reference lists in relevant articles.

RESULTS: Heart disease is the leading cause of death in NAFLD. Conversely, NAFLD is an independent cardiovascular risk factor in patients suffering from metabolic syndrome. NAFLD is associated with markers of atherosclerosis, and patients have increased risk of ischaemic heart disease. Additionally, patients with NAFLD have increased risk of cardiac dysfunction and heart failure. There are no randomized controlled trials showing clear effects of medical treatment on clinical outcomes in patients with NAFLD. However, based on evidence from small trials and extrapolation from trials evaluating patients with type 2 diabetes, some antidiabetic drugs may be beneficial on cardiovascular function in patients with NAFLD.

CONCLUSION: At present, there is promising evidence of a potential effect of antidiabetic drugs for patients with NAFLD. Future studies should address the treatment of NAFLD and the liver-related consequences but also aim at improving the cardiometabolic outcomes.

Original languageEnglish
JournalClinical Physiology and Functional Imaging
Volume39
Issue number2
Pages (from-to)122-127
ISSN1475-0961
DOIs
Publication statusPublished - 29 May 2018

ID: 53971084